4hb Feb 2022: Di India, kanser boleh memberi kesan sosial dan ekonomi yang serius, biasanya mengakibatkan kemelaratan keluarga dan ketidakadilan masyarakat. Di negara demografi muda ini, kadar kejadian kanser yang disesuaikan dengan umur yang dilaporkan masih agak rendah. Dalam populasi 1.3 bilion orang, lebih sedikit daripada 1 juta kes kanser baru dikesan setiap tahun. Dalam istilah pelarasan umur, ini mencerminkan kira-kira satu perempat daripada kejadian lelaki dan wanita yang dilihat di Eropah Barat. Kanser, sebaliknya, bertanggungjawab untuk anggaran 600000–700000 kematian di India pada tahun 2012.
Menurut analisis Global Burden of Disease Study 2019 kajian IHME, gambaran itu tidak begitu berbeza secara global. Pada 2019, bilangan kes kanser baharu melepasi 23 juta, meningkat daripada 18.7 juta pada 2010. Pada 2019, terdapat 10 juta kematian akibat kanser, meningkat daripada 8.29 juta pada 2010. Keputusan ini menunjukkan peningkatan masing-masing 20.9 peratus dan 26.3 peratus .
In both developing and developed countries, cancer is a leading cause of morbidity and mortality. The majority of the population in many low- and middle-income nations, including India, does not have access to a well-organized and well-regulated cancer care system. When a person is diagnosed with cancer, they are often forced to spend a lot of money on their own health. Such expenses can push entire families into poverty and, when paired with a lack of what are considered acceptable services, can jeopardize social stability. It can be easily said that cancer treatment in India is still in a nascent stage and huge development is required in this field.
There are two major problems cancer patients and their family members face when someone is diagnosed with cancer. One is, where will they get the best and most appropriate treatment, and two, how much money will be required for treatment? Second is the most important question, as the general population in India is still devoid of health insurance. We at CancerFax addresses both these problems. We help cancer patients find most appropriate and economical cancer treatment in India and abroad. CancerFax is working with more than 100 top cancer hospitals in 10 countries like Dana-Farber, Mayo Clinic, Boston Children’s Hospital, Sheba, Asan, Apollo, BLK, Artemis to name a few.
CAR T-Cell therapy is a breakthrough treatment for some kinds of lymphoma, leukemia and multiple myeloma. CancerFax helps patients enroll for Terapi T-Cell CAR treatment in the USA, Israel and China. Many patients who had previously relapsed blood tumors had no evidence of cancer after CAR T-Cell therapy. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies. There are more than 300 ongoing clinical trials in the world’s leading cancer centers on this therapy. CAR T-Cell therapy in India is available as clinical trials now. I hope it will be available for commercial treatment very soon.
